Valuation : Exelixis, Inc.

Market Cap 13.54B 11.66B 10.95B 9.99B 18.77B 1,288B 18.9B 130B 50.46B 653B 50.83B 49.73B 2,163B P/E 2026 *
16.9x
P/E 2027 * 14x
Enterprise Value 12.79B 11.02B 10.34B 9.44B 17.74B 1,217B 17.86B 123B 47.69B 617B 48.04B 46.99B 2,044B EV / Sales 2026 *
5.01x
EV / Sales 2027 * 4.11x
Free-Float
98.15%
Yield 2026 *
-
Yield 2027 * -
1 day+0.35%
1 week+0.16%
Current month+3.04%
1 month+3.04%
3 months+8.67%
6 months+34.12%
Current year+24.66%
1 week 53.43
Extreme 53.4283
56.9
1 month 49.97
Extreme 49.97
56.95
Current year 39.71
Extreme 39.71
57.57
1 year 33.76
Extreme 33.755
57.57
3 years 18.64
Extreme 18.64
57.57
5 years 14.87
Extreme 14.87
57.57
10 years 10.04
Extreme 10.04
57.57
Manager TitleAgeSince
Chief Executive Officer 65 2010-07-21
Director of Finance/CFO 58 2015-07-14
Chief Operating Officer 63 2016-01-31
Director TitleAgeSince
Director/Board Member 70 2004-01-31
Director/Board Member 82 2004-07-31
Chairman 77 1997-12-31
Date Insider Type Main position Quantity % Market Cap. Importance
8/10/26 Sell

Director

-9,812 0.0039%
6/1/26 Sell

Director

-9,812 0.0039%
6/1/26 Sell

Director

-3,925 0.0016%
Change 5-day change 1-year change 3-year change Capi.($)
+0.35%+0.16%+46.96%+144.04% 13.54B
-1.66%-4.96%+49.84%+88.43% 68.13B
+0.69%+2.01%+45.53%+89.67% 63.6B
+1.31%+1.81%+37.52%+12.07% 25.57B
+2.77%-1.74%-16.16%+456.51% 26.6B
-0.46%-9.94%+0.98%-15.98% 25.52B
-9.71%-0.36%+245.87%+377.68% 18.23B
-0.28%-0.14%+28.56%-20.11% 19.69B
-1.49%-6.35%+0.78%+540.26% 15.16B
+1.17%+5.48%+23.83%+200.02% 12.48B
Average -0.73%-1.89%+46.37%+187.26% 28.85B
Weighted average by Cap. -0.55%-2.00%+44.49%+148.69%

Financials

2026 *2027 *
Net sales 2.55B 2.2B 2.06B 1.88B 3.54B 243B 3.56B 24.45B 9.51B 123B 9.58B 9.38B 408B 2.9B 2.5B 2.34B 2.14B 4.02B 276B 4.05B 27.79B 10.81B 140B 10.89B 10.65B 463B
Net income 821M 707M 663M 606M 1.14B 78.08B 1.15B 7.86B 3.06B 39.6B 3.08B 3.01B 131B 1.01B 872M 818M 747M 1.4B 96.31B 1.41B 9.7B 3.77B 48.84B 3.8B 3.72B 162B
Net Debt -744M -641M -602M -549M -1.03B -70.84B -1.04B -7.13B -2.77B -35.92B -2.8B -2.73B -119B -1.62B -1.4B -1.31B -1.2B -2.25B -154B -2.27B -15.54B -6.05B -78.29B -6.09B -5.96B -259B
Logo Exelixis, Inc.
Exelixis, Inc. is an oncology company. The Company has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. It is also advancing and evolving its product pipeline portfolio, including its lead investigational asset, zanzalintinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma, for previously treated hepatocellular carcinoma and for previously treated, radioactive iodine-refractory differentiated thyroid cancer, and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer. The Company's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved the treatment of hypertension in Japan.
Employees
1,077
Date Price Change Volume
26-08-31 $54.64 +0.35% 2,246,348
26-08-28 $54.45 -1.47% 1,486,617
26-08-27 $55.26 -1.50% 1,489,697
26-08-26 $56.10 -1.09% 1,816,723
26-08-25 $56.72 +3.98% 2,024,358
Trader
Investor
Global
Quality
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
19
Last Close Price
54.64USD
Average target price
53.69USD
Spread / Average Target
-1.74%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. EXEL Stock